Alpha 2.0
Login Register
» Authors » Mario Campone

Mario Campone

Explore the profile of Mario Campone including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 287
Citations 17165
Followers 0
Related Specialties
Oncology
General Medicine
Pharmacology
Top 10 Co-Authors
Thomas Bachelot
Pascal Jezequel
Jean-Sebastien Frenel
Fabrice Andre
Florence Dalenc
Anthony Goncalves
Loic Campion
Christelle Levy
Anne Patsouris
Delphine Loussouarn
Published In
Breast Cancer Res Treat
J Clin Oncol
Bull Cancer
Lancet Oncol
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Structuring and centralizing breast cancer real-world biomarker data from pathology reports through C-LAB artificial intelligence platform
Le Borgne F, Garnier C, Morisseau C, Navarrete Y, Echeverria Y, Mir J, et al.
Digit Health . 2025 Feb; 11:20552076251323110. PMID: 40013074
Purpose: To evaluate the effectiveness of C-LAB, an artificial intelligence (AI) platform, in extracting, structuring, and centralizing biomarker data from breast cancer pathology reports within the challenging, heterogeneous dataset of...
2.
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials
Hart L, Im S, Tolaney S, Campone M, Pluard T, Sousa B, et al.
Eur J Cancer . 2025 Jan; 217:115225. PMID: 39826197
Background: Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 - advanced breast cancer (ABC)....
3.
Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic Data
Spirina Menand E, De Vries-Brilland M, Tessier L, Dauve J, Campone M, Verriele V, et al.
Biomedicines . 2025 Jan; 12(12. PMID: 39767787
Ovarian cancer is a complex disease with poor outcomes that affects women worldwide. The lack of successful therapeutic options for this malignancy has led to the need to identify novel...
4.
Monitoring concentration and lipid signature of plasma extracellular vesicles from HR metastatic breast cancer patients under CDK4/6 inhibitors treatment
Richard M, Moreau R, Croyal M, Mathiot L, Frenel J, Campone M, et al.
J Extracell Biol . 2024 Dec; 3(12):e70013. PMID: 39691590
Extracellular vesicles (EVs) are cell-derived small membrane structures that transport various molecules. They have emerged as potential circulating biomarkers for monitoring responses to cancer therapies. This study aimed to comprehensively...
5.
Link Between Metabolic Syndrome, Blood Lipid Markers, Dietary Lipids, and Survival in Women with Early-Stage Breast Cancer
Bobin-Dubigeon C, Campion L, Bossard C, Rossignol E, Frenel J, Campone M, et al.
Nutrients . 2024 Nov; 16(21). PMID: 39519412
Background/objectives: Nearly 10% of cancers could be prevented through dietary changes. In addition, breast cancer (BC) is the most common cancer in women worldwide. Inadequate diet may lead to several...
6.
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
Kacimi S, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, et al.
J Clin Oncol . 2024 Oct; 43(3):329-338. PMID: 39356975
Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV)...
7.
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities
Piffoux M, Jacquemin J, Petera M, Durand S, Abila A, Centeno D, et al.
Clin Cancer Res . 2024 Aug; 30(20):4654-4666. PMID: 39106085
Purpose: Long-term treatment-related toxicities, such as neurologic and metabolic toxicities, are major issues in breast cancer. We investigated the interest of metabolomic profiling to predict toxicities. Experimental Design: Untargeted high-resolution...
8.
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Hamilton E, Ma C, De Laurentiis M, Iwata H, Hurvitz S, Wander S, et al.
Future Oncol . 2024 Jul; 20(32):2447-2455. PMID: 39072356
Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human...
9.
Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts
Nocquet L, Roul J, Lefebvre C, Duarte L, Campone M, Juin P, et al.
Sci Rep . 2024 Jun; 14(1):14177. PMID: 38898061
Triple negative breast cancers (TNBC) present a poor prognosis primarily due to their resistance to chemotherapy. This resistance is known to be associated with elevated expression of certain anti-apoptotic members...
10.
Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study
Zhou K, Robert M, Seegers V, Blanc-Lapierre A, Savouroux S, Bigot F, et al.
PLoS One . 2024 May; 19(5):e0304556. PMID: 38820299
Background: Longer times between diagnosis and treatments of cancer patients have been estimated as effects of the COVID-19 pandemic. However, relatively few studies attempted to estimate actual delay to treatment...